Newswise — January 9, 2020 – New research into the biology of depression, along with new and evolving technologies, provides the basis for developing the next generation of treatments for major depressive disorder (MDD), according to the special January/February issue of Harvard Review of Psychiatry. The journal is published in the Lippincott portfolio by Wolters Kluwer.
“By embracing a multifactorial understanding of MDD, by attending carefully to the sex difference in its prevalence and manifestation, and by harnessing new technology, we should be increasingly able to prevent and treat depression,” writes Guest Editor Diego A. Pizzagalli, PhD, of McLean Hospital, Belmont, Mass.
Research in Five Key Areas May Point to New Treatments for Depression
Contributed by international experts, the five articles in the special issue provide updates on neuroscience and technology that may inform the development of much-needed treatments for depression. Topics include:
Gender Differences in Depression. After age 12, MDD is twice as common in girls compared to boys. Studies have yielded insights into the affective, biological, and cognitive factors contributing to this gender difference – for example, negative emotionality, pubertal hormones, and negative cognitive style. While each factor has a relatively small effect on risk, past and present stressors amplify their impact. Continued research may lead to evidence-based treatments that better take into account the particular needs and circumstances of girls and women.
Neuroscience and Behavioral Interventions. “Neuroscience-based augmentation strategies” are being pursued to address two key aspects of depression: anhedonia (loss of interest in pleasurable activities) and cognitive deficits/biases. An approach called Positive Affect Treatment targets issues related to motivation, reward attainment, and reward learning. In an initial clinical trial, this approach showed benefits including decreases in depression symptoms, suicidal thoughts, and stress.
Role of the Microbiome. Evidence suggests that the gut microbiome – the community of bacteria and other microbes living in the intestinal tract – may contribute to the development and persistence of MDD. The microbiome is altered in patients with depression, and commonly used antidepressant drugs affect the microbiome. For example, studies have suggested that a diet high in anti-inflammatory foods (such as the Mediterranean diet) may shorten episodes of depression.
Opioid-Based Therapies. Compelling evidence suggests that abnormal opioid signaling may play a role in the development of MDD. This may help to explain why many patients don’t respond to current antidepressant medications. Opioid mechanisms might also account for rapid antidepressant responses to the anesthetic drug ketamine. Strategies targeting one or more of the four opioid receptor subtypes might open new approaches to treating MDD and other stress-related disorders.
Technology in Depression Treatment. Wearable devices, global positioning systems (GPS), and other technologies may provide valuable tools for understanding the wide variation in symptom and disease expression (phenotype) of MDD. For example, GPS devices or fitness trackers may provide useful information on symptoms of social isolation, physical inactivity, and sleep disruption. These and other approaches such as natural language processing and ecological momentary assessment could provide real-time assessment of depression’s impact on the lives of individual patients.
While current evidence-based treatments, including antidepressant medications and psychotherapy, are helpful for many people, an “unacceptably high” proportion of patients with depression derive no benefit from these treatments. “There’s an acute need for new understandings of depression and its impact on patients’ lives,” Dr. Pizzagalli comments. “We hope the insights provided by the special issue papers will help to spur the development of new and better treatment approaches that our patients urgently need.”
About the Harvard Review of Psychiatry
The Harvard Review of Psychiatry is the authoritative source for scholarly reviews and perspectives on a diverse range of important topics in psychiatry. Founded by the Harvard Medical School Department of Psychiatry, the journal is peer reviewed and not industry sponsored. It is the property of Harvard University and is affiliated with all of the Departments of Psychiatry at the Harvard teaching hospitals. Articles encompass major issues in contemporary psychiatry, including neuroscience, epidemiology, psychopharmacology, psychotherapy, history of psychiatry, and ethics.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2018 annual revenues of €4.3 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 18,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit http://healthclarity.wolterskluwer.com and follow us on LinkedIn and Twitter @WKHealth.